RxDoctor Payments Data

Rachel Jacob, NP

Family · Glendale, AZNPI 1336680461

Payments from drug & device makers

$11,795in general payments, 2019–2025

Across 670 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols USA, LLC$1K
  • GSK$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$964
  • Sanofi$765
  • Mylan Specialty L.p.$691
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$11,48597%
  • Education$3103%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,795 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$1,572
Medicare patients
16
Services billed
16

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate63$805,367
Prolastin CAlpha-1-Proteinase Inhibitor41$354,535
Trelegy ElliptaFluticasone/Umeclidin/Vilanter442$352,987
ZemairaAlpha-1-Proteinase Inhibitor34$295,434
GlassiaAlpha-1-Proteinase Inhibitor13$151,667
Breztri AerosphereBudesonide/Glycopyr/Formoterol103$65,159
Stiolto RespimatTiotropium Br/Olodaterol Hcl104$64,184
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr107$60,003
Breo ElliptaFluticasone/Vilanterol94$47,874
Spiriva RespimatTiotropium Bromide37$24,324
SymbicortBudesonide/Formoterol Fumarate75$21,258
Albuterol Sulfate HfaAlbuterol Sulfate499$12,118
Fluticasone-SalmeterolFluticasone Propion/Salmeterol98$11,439
Wixela InhubFluticasone Propion/Salmeterol89$9,176
Arnuity ElliptaFluticasone Furoate25$6,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$964$893,874204 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$1,426$467,710668 claims
Grifols USA, LLCProlastin C$1,484$354,53541 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$628$151,66713 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,324$86,417178 claims
Eisai Inc.Dayvigo$19$3,92512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →